Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta Limited has strengthened its leadership with new board members and a clinical advisory team to support its growth strategy. The company has signed its first non-binding term sheet for its ‘East to West’ cellular therapy strategy and continues to enhance its AD-214 anti-fibrotic drug candidate’s value, aiming to secure partnerships and financing for further development.
More about AdAlta Ltd.
AdAlta Limited is a developer of next-generation protein and cell therapeutic products, focusing on the rapidly growing cellular immunotherapy market and anti-fibrotic drugs. The company operates primarily in the biotechnology sector, aiming to bring Asian cellular therapy innovations to Western markets and developing therapeutics for fibrotic diseases.
YTD Price Performance: -15.00%
Average Trading Volume: 350,569
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.73M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.
